This story on ABT about it's AID drug sound kind of ugly (see http://biz.yahoo.com/rf/980918/bal.html ). The good news is that ABT has a liquid form of the drug on the market, but it my spook some into bolting the stock leading to a drop in the stock price by the next investment date. Just a reminder, the next window of opportunity for the DRIP is September 24.
The news about Norvir may seem to be worse than it actually is. ABT says the liquid form is plentiful, so patients will have no problem continuing their medication as long as they can swallow the liquid form, which is said to taste bad. I have to believe that ABT scientists are working night and day to solve the capsule problem.